Boston Scientific Corporation filed its quarterly report on Form 10-Q with the SEC on November 2, 2026, covering the three and nine months ended September 30, 2026, and reporting net sales of $5.138 billion for the third quarter.

Key Highlights

  • Quarterly net sales: $5.138 billion for the three months ended September 30, 2026, compared to $5.065 billion in the same period of 2025, according to the filing.
  • Nine-month net sales: $15.784 billion for the nine months ended September 30, 2026, up from $14.788 billion in the prior-year period, as reported.
  • Net income attributable to Boston Scientific common stockholders: $582 million for Q3 2026, compared to $755 million in Q3 2025.
  • Diluted earnings per share: $0.40 for the three months ended September 30, 2026, versus $0.51 in the year-earlier quarter.
  • Nine-month net income attributable to Boston Scientific common stockholders: $2.830 billion, up from $2.226 billion for the nine months ended September 30, 2025.
  • Shares outstanding: 1,449,473,222 shares of common stock as of October 29, 2026, per the cover page.
  • Litigation-related net charges: $81 million for Q3 2026 and $157 million for the nine months ended September 30, 2026, with no comparable charges in the prior-year periods.

Boston Scientific Q3 2026 Financial Results and Operating Details

According to the filing, Boston Scientific Corporation (NYSE:BSX) reported third-quarter net sales of $5.138 billion, an increase from $5.065 billion in the three months ended September 30, 2025. Gross profit for Q3 2026 was $3.428 billion, compared to $3.542 billion in Q3 2025. Cost of products sold, excluding amortization, rose to $1.710 billion from $1.523 billion year over year, the filing stated. Operating income for the quarter was $828 million, down from $1.048 billion in the prior-year period.

The filing disclosed several notable items affecting the quarter. Restructuring net charges were $63 million for Q3 2026, compared to net credits of $8 million in Q3 2025. Intangible asset impairment charges of $39 million were recorded in Q3 2026, with no comparable charge in Q3 2025. Contingent consideration resulted in a net benefit of $32 million for the quarter. Interest expense was $100 million for Q3 2026, versus $87 million in the prior-year quarter. Income tax expense was $153 million for the three months ended September 30, 2026, compared to $183 million in the same period of 2025.

For the nine months ended September 30, 2026, the filing reported operating income of $3.107 billion on net sales of $15.784 billion. Selling, general and administrative expenses for the nine-month period were $5.266 billion, and research and development expenses totaled $1.589 billion. The filing also listed, among its risk factors, disruptions from cybersecurity events, specifically referencing "the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results" as a forward-looking risk. Basic and diluted weighted-average shares outstanding for the nine months ended September 30, 2026 were 1,468.0 million and 1,473.9 million, respectively.

What Was Disclosed

Boston Scientific's Form 10-Q for the period ended September 30, 2026 disclosed quarterly net sales of $5.138 billion, diluted EPS of $0.40, litigation-related charges of $81 million, and nine-month net income attributable to common stockholders of $2.830 billion, along with risk factor disclosures including a referenced cybersecurity incident.